Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
Multiplex Assay Kit for Osteoglycin (OGN) ,etc. by CBA (Cytometric Bead Array)
OIF; SLRR3A; Mimecan Proteoglycan; Osteoinductive Factor
- Product No.CMC688Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- Sample Typetissue homogenates, cell lysates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length4h
- Detection Range0.0098-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.0033ng/mL.
- DownloadInstruction Manual
- UOM 48T96T
- FOB
US$ 605
US$ 864
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Osteoglycin (OGN) ,etc. by CBA (Cytometric Bead Array).
No significant cross-reactivity or interference between Osteoglycin (OGN) ,etc. by CBA (Cytometric Bead Array) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Osteoglycin (OGN) ,etc. by CBA (Cytometric Bead Array) and the recovery rates were calculated by comparing the measured value to the expected amount of Osteoglycin (OGN) ,etc. by CBA (Cytometric Bead Array) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 84-101 | 92 |
| EDTA plasma(n=5) | 94-102 | 98 |
| heparin plasma(n=5) | 96-104 | 101 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Osteoglycin (OGN) ,etc. by CBA (Cytometric Bead Array) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Osteoglycin (OGN) ,etc. by CBA (Cytometric Bead Array) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Osteoglycin (OGN) ,etc. by CBA (Cytometric Bead Array) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 78-90% | 97-105% | 90-97% | 86-94% |
| EDTA plasma(n=5) | 78-102% | 83-99% | 97-105% | 96-103% |
| heparin plasma(n=5) | 80-98% | 96-105% | 89-96% | 90-97% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| Bone. | Association of osteoglycin and FAM5C with bone turnover markers, bone mineral density, and vertebral fractures in postmenopausal women with type 2 diabetes mellitus. pubmed:27836731 |
| Tohoku journal of experimental medicine | Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease. pubmed:28824047 |
| Molecular Metabolism | Osteoglycin, a novel coordinator of bone and glucose homeostasis Pubmed:29799418 |
| Journal of Experimental & Clinical Cancer Research | Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway Pubmed:29499765 |
| Journal of Human Hypertension | Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patients Pubmed:29867136 |
| Cell Reports | Transforming Growth Factor-β3 Regulates Adipocyte Number in Subcutaneous White Adipose Tissue Pubmed: 30332637 |
| J Clin Endocrinol Metab | Osteoglycin across the adult lifespan 34850904 |
| Catalog No. | Related products for research use of Mus musculus (Mouse) Organism species | Applications (RESEARCH USE ONLY!) |
| RPC688Mu02 | Recombinant Osteoglycin (OGN) | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPC688Mu01 | Recombinant Osteoglycin (OGN) | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC688Mu01 | Polyclonal Antibody to Osteoglycin (OGN) | WB; IHC |
| PAC688Mu02 | Polyclonal Antibody to Osteoglycin (OGN) | WB; IHC; ICC; IP. |
| LAC688Mu71 | Biotin-Linked Polyclonal Antibody to Osteoglycin (OGN) | WB |
| SEC688Mu | ELISA Kit for Osteoglycin (OGN) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMC688Mu | Multiplex Assay Kit for Osteoglycin (OGN) ,etc. by FLIA (Flow Luminescence Immunoassay) | FLIA Kit for Antigen Detection. |
| CMC688Mu | Multiplex Assay Kit for Osteoglycin (OGN) ,etc. by CBA (Cytometric Bead Array) | FLIA Kit for Antigen Detection. |

